Nicotinamide Mononucleotide in Patients Undergoing Cardiac Surgery
Sponsor: Brigham and Women's Hospital • ClinicalTrials.gov ID: NCT07013591
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective cardiac surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.
Interventions
-
MIB-626
(Drug)
An orally-administered stable crystalline tablet formulation of NMN
-
Placebo
(Other)
matching placebo tablets
Eligibility criteria
Conditions
Locations
- Brigham and Women's Hospital — Boston, Massachusetts, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record